You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
BridgeBio reported $353.2 million in third-quarter 2026 revenue, including $253.2 million of U.S. Atrube net product revenue, up approximately 134% year-over-year. BBP418, infagratinib, and incalorate have PDUFA dates of November 27th, February 4, 2027, and May 8, 2027.
BridgeBio Pharma reported a nine-month net loss of $382.9 million versus $538.3 million in 2025, while net product revenue increased $440.0 million. It raised $933.9 million through preferred stock, with $500.0 million still available under its ATM offering.
BridgeBio Pharma, Inc. reported third-quarter total revenues, net of $353.2 million, including $253.2 million of U.S. Attruby net product revenue. PDUFA dates are November 27, 2026 for BBP-418, February 4, 2027 for oral infigratinib, and May 8, 2027 for encaleret.
BridgeBio Pharma, Inc. announced FDA acceptance of oral infigratinib for children with achondroplasia with Priority Review, assigning a PDUFA target action date of February 4, 2027.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. BridgeBio reported third-quarter revenue of $353.2 million, including $253.2 million of U.S. Attruby net product revenue, an $11.6 million operating loss versus $145.2 million a year earlier, and $1.5 billion of cash. Comparative real-world evidence favored Attruby over tafamidis, while BBP-418, infigratinib, and encaleret reported regulatory, clinical, and launch-readiness progress ahead of three potential launches.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| U.S. Attruby net product revenue | $253.35M | FY2026 Q3 | +134.3% |
|
|
|||
| New ADH diagnoses per month | 70 | from its introduction in October 2023 through June 2026 | — |
| Propensity score-matched analysis patient pairs from TriNetX | 286 | presented at SCAI 2026 Scientific Sessions | — |
| Unique ADH patients identified under dedicated ICD-10 code | 2,200 | from its introduction in October 2023 through June 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BBIO
this stock
BridgeBio Pharma, Inc.
|
$15.25B | +2.4% | +126.3% | — | 10.7% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
BridgeBio Pharma, Inc. reported third-quarter total revenues, net of $353.2 million, including $253.2 million of U.S. Attruby net product revenue. PDUFA dates are November 27, 2026 for BBP-418, February 4, 2027 for oral infigratinib, and May 8, 2027 for encaleret.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BBIO | +5.4% | +17.9% | +15.6% | +4.5% | +2.4% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +2.8% | +19.1% | +15.1% | +4.7% | -8.3% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
